Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Cancer Female: early-phase trial registry
22 of 47 indexed Breast Cancer Female trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #307 of 28,707 conditions by registered trial count.
47 US clinical trials · 22 currently recruiting · #307 of 28,707 conditions by registered trial count
Breast Cancer Female: 47 US clinical trials tracked, 22 recruiting.
Breast Cancer Female is the subject of 47 registered US clinical trials on ClinicalTrials.gov, 22 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 3 of these trials.
Enrollment posture brief
Registry condition breast-cancer-female
OPEN 22 | RECR 47% | LATE 1 | EARLY 14 | RANK #307 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Myelofibrosis (47% recruiting · 62 trials)
Breast Cancer Female lists 22 open slots (47% of 47 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Breast Cancer Female on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Cancer Female is recruiting above its size-band peers.
22 of 47 indexed trials (46.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Cancer Female trials is spread across many organizations.
Dana-Farber Cancer Institute accounts for 3 of 47 trials (6.4%). 41 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Cancer Female enrolment sits around 100 participants.
Median target enrolment is 100 among the 47 trials that report a genuine target (sentinel values excluded). 23 of those (48.9%) plan for fewer than 100 participants.
-
Breast Cancer Female research is mostly interventional.
37 interventional and 10 observational studies make up this index (78.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
47 total, page 1 of 1
UCF MammoChat: Image Repository
University of Central Florida
NCT07214883
Biennial CEM in Women With a Personal History of Breast Cancer
Wendie Berg
NCT06105749
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
Breast Cancer Trials, Australia and New Zealand
NCT06445738
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
Memorial Sloan Kettering Cancer Center
NCT05561842
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
University of Arizona
NCT05676255
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
University of Virginia
NCT06507618
Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women
Cedars-Sinai Medical Center
NCT05298605
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
Dana-Farber Cancer Institute
NCT05535192
Microbiome and Association With Implant Infections
University of California, San Francisco
NCT05020574
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Baylor Breast Care Center
NCT05020860
GammaPod Registry and Quality of Life Nomogram
University of Maryland, Baltimore
NCT03562273
Effects of Chemotherapy on Cognitive Function in Breast Cancer Patients & Non-Cancer Control Subjects With Optional Sub-Study Research Brain MRI
University of Rochester
NCT03137095
Breast Cancer Resiliency Through Exercise Program (B-REP)
University of Michigan Rogel Cancer Center
NCT06100263
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
NCT06439693
THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation
The University of Texas Medical Branch, Galveston
NCT06395506
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Sarah Sammons, MD
NCT06176261
Cognitive Rehabilitation Following Breast Cancer Treatment
University of Missouri-Columbia
NCT06545045
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
Dana-Farber Cancer Institute
NCT06322888
Time Restricted Eating During Chemotherapy for Breast Cancer
University of Illinois at Chicago
NCT05259410
EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NCT06115486
Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors
University of Utah
NCT07120100
Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management
University of Kansas Medical Center
NCT07242118
Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania
Wendie Berg
NCT04085510
Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information in Women
University of Colorado, Denver
NCT06441474
Assessment of Breast Cancer Patients Satisfaction and Health Related Quality of Life Outcomes
Henry Ford Health System
NCT03333122
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial
Wake Forest University Health Sciences
NCT06216574
Robotic vs. Open NSM for Early Stage Breast Cancer
Intuitive Surgical
NCT05720039
Accelerated Partial Breast Irradiation Study
Sentara Norfolk General Hospital
NCT03437395
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03384914
Diet, Hepcidin, and Chemotherapy RDI
George Washington University
NCT06483997
IORT-Breast at Medical Center Navicent Health
Wake Forest University Health Sciences
NCT04595435
Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer
Shayna Showalter, MD
NCT04272801
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
Filipa Lynce, MD
NCT06351332
Ultrahypofractionation and Normal Tissue Toxicity
Massachusetts General Hospital
NCT05912231
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03387553
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
Adrienne G. Waks
NCT06100874
Abbreviated MBCT for Depression in Older African American/Black Breast Cancer Survivors
Case Comprehensive Cancer Center
NCT06336538
A Post-Market Clinical Trial to Evaluate the Performance and Operation of the Brevera Breast Biopsy System
Hologic
NCT03300206
Using Behavioral Economics to Achieve Improved Healthy Behavior Outcomes in Breast Cancer Survivors
Texas Tech University Health Sciences Center
NCT02938780
PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
Washington University School of Medicine
NCT03084536
Stress Reactivity Among African American Breast Cancer Survivors
Medical University of South Carolina
NCT03881085
Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
University of Texas Southwestern Medical Center
NCT03747042
A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
Translational Research in Oncology
NCT03004534
Living Well After Breast Surgery
University of Texas at Austin
NCT03834532
Effects of Aromatase Inhibitor Therapy on Muscle Function
Tarah J Ballinger, MD
NCT03581552
Streaming Web-based Exercise At Home: A Pilot Study
Celina Shirazipour
NCT04282967
REJOIN Trial for Older Breast Cancer Survivors
Wake Forest University Health Sciences
NCT03955627
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 10 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Breast Cancer Female records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Breast Cancer Female trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Breast Cancer Female page
47 registered trials, 22 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 22 Breast Cancer Female trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dana-Farber Cancer Institute sponsors the most Breast Cancer Female trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Cancer Female condition card totals 47 registered trials; most-linked intervention Paclitaxel; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.